Imagion BiosystemsIBXXF FCF Yield % is -71.59 as of Jun. 30, 2026. The stock has 4 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 94.39% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Imagion Biosystems's FCF Yield % or its related term are showing as below:
IBXXF'
s FCF Yield % Range Over the Past 10 Years
Min: -1328.72 Med: -71.69 Max: -3.1
Current: -71.59
During the past 9 years, the highest FCF Yield % of Imagion Biosystems was -3.10%. The lowest was -1328.72%. And the median was -71.69%.
IBXXF's FCF Yield % is ranked worse than 94.39% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.475
vs IBXXF: -71.59
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Imagion Biosystems FCF Yield % Related Terms
Imagion Biosystems FCF Yield % Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Imagion Biosystems's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (IBXXF) has a FCF Yield % of -71.59 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Imagion Biosystems and its competitors. According to the industry distribution chart, Imagion Biosystems ranks #202 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 94.4%.
Is Imagion Biosystems' FCF Yield % too high?
Imagion Biosystems' current FCF Yield % is -71.59. Based on the distribution chart, Imagion Biosystems ranks #202 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #202 out of 214 companies for FCF Yield %. This places Imagion Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Imagion Biosystems and its competitors. Imagion Biosystems's current FCF Yield % is -71.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (IBXXF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.83, compared to a current price of $0.03 — trading 98.9% below its estimated fair value. The current FCF Yield % is -71.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Imagion Biosystems (IBXXF), the current FCF Yield % is -71.59 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBXXF has been successfully added to your 